liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Age-dependent decline of beta-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study
Cambridge Institute Public Heatlh, England .
University of Campus Biomed, Italy .
University of Dusseldorf, Germany University of Dusseldorf, Germany .
Semmelweis University, Hungary .
Show others and affiliations
2014 (English)In: Diabetes, obesity and metabolism, ISSN 1462-8902, E-ISSN 1463-1326, Vol. 16, no 3, 262-267 p.Article in journal (Refereed) Published
Abstract [en]

AimsC-peptide secretion is currently the only available clinical biomarker to measure residual -cell function in type 1 diabetes. However, the natural history of C-peptide decline after diagnosis can vary considerably dependent upon several variables. We investigated the shape of C-peptide decline over time from type 1 diabetes onset in relation to age at diagnosis, haemoglobin A1c (HbA1c) levels and insulin dose. MethodsWe analysed data from 3929 type 1 diabetes patients recruited from seven European centres representing all age groups at disease onset (childhood, adolescence and adulthood). The influence of the age at onset on -cell function was investigated in a longitudinal analysis at diagnosis and up to 5-years follow-up. ResultsFasting C-peptide (FCP) data at diagnosis were available in 3668 patients stratified according to age at diagnosis in four groups (less than5years, n=344; greater than5yearsless than10years, n=668; greater than10yearsless than18years, n=991; greater than18years, n=1655). FCP levels were positively correlated with age (pless than0.001); the subsequent decline in FCP over time was log-linear with a greater decline rate in younger age groups (pless than0.0001). ConclusionsThis study reveals a positive correlation between age at diagnosis of type 1 diabetes and FCP with a more rapid decline of -cell function in the very young patients. These data can inform the design of clinical trials using C-peptide values as an end-point for the effect of a given treatment.

Place, publisher, year, edition, pages
Wiley , 2014. Vol. 16, no 3, 262-267 p.
Keyword [en]
beta cell; clinical trial; type 1 diabetes
National Category
Clinical Medicine Cell and Molecular Biology
URN: urn:nbn:se:liu:diva-104835DOI: 10.1111/dom.12216ISI: 000330564800009OAI: diva2:699613
Available from: 2014-02-28 Created: 2014-02-28 Last updated: 2015-03-30

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Ludvigsson, JohnnyNordwall, Maria
By organisation
Division of Clinical SciencesFaculty of Health SciencesDepartment of Paediatrics in LinköpingDepartment of Paediatrics in Norrköping
In the same journal
Diabetes, obesity and metabolism
Clinical MedicineCell and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 179 hits
ReferencesLink to record
Permanent link

Direct link